Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 7c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($0.94), $0.07 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• KB Home (KBH) Tops Q3 EPS by 16c
• Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes